Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27267015 | 0.86 | CRBN (0.47) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30930626 | 0.86 | CRBN (0.47) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL29188615 | 0.85 | CRBN (0.57) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31739101 | 0.82 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL30496995 | 0.82 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL25246941 | 0.82 | CRBN (0.46) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL19771065 | 0.82 | CRBN (0.61) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31739095 | 0.82 | CRBN (0.45) | CRBNDDB1IKZF3BCL2L11BCL2 | |
| SCHEMBL31736587 | 0.81 | IKZF2 (0.42) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL31736939 | 0.81 | IKZF2 (0.42) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025234888-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025233481-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2025-11-13 | — | — | WO | disclosed |
| EP-4612140-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2025-09-10 | — | — | EP | disclosed |
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS | 2025-07-03 | — | — | US | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| EP-4499629-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024096753-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024096753-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024094819-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024094819-A1 | NEK7 DEGRADERS AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023183919-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214991-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | IKZF1, IKZF2, IKZF3 | CRBN 371/4885DDB1 2624/4885ALDH1A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.